A multi-centre study to compare meropenem and cefotaxime and metronidazole in the treatment of hospitalized patients with serious infections
| Autor: | D J Leaper, E P Dewar, E W Taylor, S Mehtar |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty Cefotaxime medicine.drug_class Antibiotics Meropenem Metronidazole Internal medicine polycyclic compounds medicine Humans Pharmacology (medical) Prospective Studies Adverse effect Aged Antibacterial agent Aged 80 and over Pharmacology business.industry Incidence (epidemiology) Bacterial Infections Middle Aged biochemical phenomena metabolism and nutrition bacterial infections and mycoses Anti-Bacterial Agents Surgery Discontinuation Hospitalization Treatment Outcome Infectious Diseases Female Thienamycins business medicine.drug |
| Zdroj: | Journal of Antimicrobial Chemotherapy. 39:631-638 |
| ISSN: | 1460-2091 |
| DOI: | 10.1093/jac/39.5.631 |
| Popis: | We conducted a prospective, multi-centre, open, randomized study in 11 UK hospitals to compare iv meropenem 1 g tds with the combination of iv cefotaxime 1 g tds and iv metronidazole 500 mg tds in patients with serious infections. One hundred and sixty-one patients were enrolled, of whom 131 were clinically evaluable (meropenem, n = 68; cefotaxime/ metronidazole, n = 63). The most common infections were subsequent to intra-abdomin al pathology (meropenem, n = 77%; cefotaxime/metronidazole, n = 75%), and were usually accompanied by septicaemia (meropenem, n = 61%; cefotaxime/metronidazole, n = 53%). The incidence of a satisfactory clinical response was similar in the two groups at the end of treatment (93% for meropenem; 92% for cefotaxime/metronidazole) and up to 8 weeks later (96% for meropenem; 93% for cefotaxime/metronidazole). Satisfactory bacteriological response (success or presumed success) was recorded at the end of therapy in 86% of meropenem and 88% of cefotaxime/me tronidazole patients. Adverse events were reported in 32% of meropenem and 25% of cefotaxime/metronidazole patients, and most were mild or moderate and did not require discontinuation of therapy. Twenty-one patients (ten meropenem and 11 cefotaxime/metronidazole) died during the trial, underlining the severity of the infections being treated in this group of patients. None of the deaths was thought to be related to study therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|